Page 862 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

840 Index

Time to progression (TTP), 342–343 Transitional cell carcinoma (TCC), 134–135, Trousseau’s syndrome, 104
Tissue biopsy, in canine osteosarcoma, 529, breed predilections for, 646t TTP. see Time to progression
666t
530f
Tubulin, 182
VetBooks.ir Tissue specimen, preparation of, 129 as canine urinary bladder cancer, 645 β-tubulin, 185
cell characteristics in, 130f
TKI. see Tyrosine kinase inhibitor
Tulsa Registry of Canine and Feline
TLRs. see Toll-like receptors comparative aspects of, 653 Neoplasms, 83t
TNM staging, for canine urinary bladder diagnosis of, 646–648 Tumor
tumors, 646b differential diagnoses of, 646–648 cause of, 1
Tobacco smoke, environmental, 14 insecticides and herbicides causing, 15 classification of, 132
Toceranib (Palladia), 262 neutering/spaying and, 92 immunohistochemistry, 71
angiogenesis inhibition and, 263 nutritional risk factors for, 301 control of growth, 231–234
development/approval of use, 345 presentation of, 646–648 cytopathology of, 126
for mast cell tumors, 392 prognosis for, 652 definition of, 62
for thyroid gland neoplasia, in risk factors for, 645, 646t development of, 63
dogs, 577 sites for, 645 immune system control of, 231–234
Tolfenamic acid, 293t–294t staging of, 646b features of importance and grades for, 68t
Toll-like receptor 9 (TLR9), 233–234 treatment of ground substance from, 130
Toll-like receptors (TLRs), 237 localized therapy, 651 heterogeneity of, 67
Tonsillar squamous cell carcinoma, radiation therapy, 649 hypoxic, 210
445, 446f surgery, 648–649 immune system and
Topoisomerase I, 185 systemic medical therapy, 649–651, failure to activate, 232–233
Topoisomerase II, 185 649t–650t mechanisms of evasion, 231–234, 232f
Topoisomerase inhibitor, 195–196 vegetables and, 645–646 immunohistochemical markers/panels for,
epipodophyllotoxins as, 196 view of 72t–73t
Total ear canal ablation (TECA), 361 by cystoscopy, 647f incurable, treatment of, 256
Total parenteral nutrition formulation sheet, cystosonography, 648f microenvironment of, 263
307f Translocation breakpoint, 42 miscellaneous, 773–810
Toxicity, chemotherapy-induced, 187t Transmissible venereal tumor (TVT) canine transmissible venereal tumor, 781
Trachea, cancer of, 505 canine, 781 hemangiosarcoma, 773
clinical signs of, 505 diagnostic techniques and workup, 783 histiocytic diseases, 791
comparative aspects of, 507 history and clinical signs, 782, 783f–784f mesothelioma, 784–785
diagnostic techniques for, 505–506, incidence and risk factors, 781 neoplasia of the heart, 787
505f–506f pathology and natural behavior, 781–782 thymoma, 778
history for, 505 prognosis, 784 nomenclature for, 64t
incidence of, 505 therapy, 783–784 paraneoplastic syndromes and, 98, 99b
natural behavior of, 505 characteristics of, 144 personalized medicine for, 347–348
pathology of, 505 fine-needle aspiration of, 144f regulatory T cells by, induction of, 233
prognosis of, 506 Transsphenoidal hypophysectomy of skin and subcutaneous tissues, 352–366
risk factors for, 505 for canine pituitary-dependent surgery of
therapy for, 506 hypercortisolism, 567–568 considerations of, 158
Traditional chemoembolization, 178 for feline pituitary-dependent pain after, 287t
Traditional Chinese herbal medicine hyperadrenocorticism, 568–569 Tumor antigens (TAs), 239
(TCHM), 332 Transverse incision, for biopsy, 162 immunization against, 239–240
Tramadol Trapping phenomenon, 54 using dendritic cells, 240
dose and effects of Trastuzumab (Herceptin), 261–262 using plasmid DNA, 239–240
for cats, 293t–294t Trauma/chronic inflammation, 16 Tumor-associated eosinophilia, 103
for dogs, 292t Traumatic catheterization, 127 Tumor-associated macrophages (TAM), 233
efficacy of, 295 bladder mass cells collected by, 129f Tumor-causing virus
side effects of, 295 Treg cell in cats
Transcription factor, gene expression and, prognosis and, 233 feline leukemia virus, 22–25
42–43 T-cell conversion to, 233 papillomavirus, 21–22
Transcriptional targeting, 254 Trichoblastoma, 358, 358f retrovirus, 22
viral vector specificity and, 253f Trichoepithelioma, 358–359 in dogs, papillomavirus, 19–21
Transdermal fentanyl patch, 292t–294t Tricholemmoma, 358 Tumor cell
Transductional targeting, 253 Tricyclic antidepressant, 296 accelerated repopulation of, 211–212
viral vector specificity and, 253f Trilostane anoikis and, 6
Transforming growth factor-beta (TGF-β), for canine adrenocortical tumors, 572 arrest of, 54
100 for canine pituitary-dependent biology, 36–60
prostate tumors and, 632 hypercortisolism, 567 classification of, 40
Transient receptor potential channel, for feline pituitary-dependent benign, 40
vanilloid subfamily member 1 hyperadrenocorticism, 568–569 cancer, 40
(TRPV1), 299 Trisomy 15, 269 in situ, 40